Changing the course of cancer treatment
We harness the power of the body's immune system to keep tumor cells in check without harming health or quality of life.
Mendus to present novel data supporting the broad potential of its proprietary cancer vaccine platform at CICON23
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, will present novel clinical and preclinical data on the mode of action of its...
Mendus Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference in September
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the Company will present a company presentation and...
Mendus publishes preclinical data demonstrating synergies of ilixadencel and 4-1BB-targeting immunotherapies
INTRATUMORAL PRIMING BOOSTED THE THERAPEUTIC EFFICACY OF ANTI-4-1BB ANTIBODY TREATMENT AND RESULTED IN A MORE TREATMENT-SUPPORTIVE TME Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical...
Publication of Year-end Report 2022
Publication of Annual Report 2022
Annual General Meeting
Publication of Q1 Report
Publication of Q2 Report
Publication of Q3 Report
Publication of Year-end Report 2023
Keep up to date
Join our mailing list to receive our latest news.